

Donatella Gambini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2734537/publications.pdf>

Version: 2024-02-01

29
papers

460
citations

840776

11
h-index

713466

21
g-index

29
all docs

29
docs citations

29
times ranked

663
citing authors

#	ARTICLE	IF	CITATIONS
1	Triage process for the assessment of coronavirus disease 2019â€positive patients with cancer: The ONCOVID prospective study. <i>Cancer</i> , 2021, 127, 1091-1101.	4.1	9
2	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2628.	4.1	21
3	The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. <i>Viruses</i> , 2021, 13, 508.	3.3	3
4	10P The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+ breast cancers. <i>Annals of Oncology</i> , 2021, 32, S25.	1.2	0
5	COVID-19 Vaccination in Patients with Classic Kaposiâ€™s Sarcoma. <i>Vaccines</i> , 2021, 9, 632.	4.4	1
6	1555TiP A phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS): The PULSAR trial. <i>Annals of Oncology</i> , 2021, 32, S1128.	1.2	0
7	Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2â€3 studies. <i>Radiotherapy and Oncology</i> , 2021, 164, 13-19.	0.6	6
8	Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. <i>BMC Cancer</i> , 2021, 21, 1152.	2.6	9
9	Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 931-940.	1.8	7
10	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103059.	4.4	29
11	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1461.	4.1	25
12	Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	29
13	Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 138.	2.4	28
14	<i>NF1</i> Alterations are Linked to Increased HER2 Expression in Breast Cancerâ€™Letter. <i>Cancer Prevention Research</i> , 2019, 12, 195-196.	1.5	3
15	Columnar Cell Lesion and Apocrine Hyperplasia of the Breast: Is There a Common Origin? The Role of Prolactin-induced Protein. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 508-514.	1.2	11
16	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky056.	2.9	71
17	Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. <i>BMC Cancer</i> , 2018, 18, 935.	2.6	32
18	Lymphovascular invasion and extranodal tumor extension as risk indicators of breast cancer-related lymphedema.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12609-e12609.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	11
20	Secondary Breast Angiosarcoma and Paclitaxel-dependent Prolonged Disease Control: Report of Two Cases and Review of the Literature. <i>Tumori</i> , 2015, 101, e60-e63.	1.1	9
21	Remission of autoimmune hyperthyroidism after chemotherapy for cancer. <i>Internal and Emergency Medicine</i> , 2014, 9, 109-111.	2.0	1
22	Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?. <i>Anticancer Research</i> , 2014, 34, 7361-5.	1.1	3
23	Uncommon Breast Malignancies: Presentation Pattern, Prognostic Issue and Treatment Outcome in an Italian Single Institution Experience. <i>Tumori</i> , 2013, 99, 39-44.	1.1	1
24	Uncommon breast malignancies: presentation pattern, prognostic issue and treatment outcome in an Italian single institution experience. <i>Tumori</i> , 2013, 99, 39-44.	1.1	1
25	Paclitaxel-Dependent Prolonged and Persistent Complete Remission Four Years from First Recurrence of Secondary Breast Angiosarcoma. <i>Tumori</i> , 2009, 95, 828-831.	1.1	22
26	Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma. <i>Tumori</i> , 2009, 95, 828-31.	1.1	8
27	Antiphospholipid antibodies and endothelial cells: an unending story. <i>Lupus</i> , 1995, 4, 169-171.	1.6	8
28	Antiphospholipid Antibodies and Endothelial Cells. <i>Lupus</i> , 1994, 3, 267-269.	1.6	15
29	Characterization of the Endothelial Surface Proteins Recognized by Anti-Endothelial Antibodies in Primary and Secondary Autoimmune Vasculitis. <i>Clinical Immunology and Immunopathology</i> , 1994, 70, 211-216.	2.0	97